Skip to content
lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Rapport Therapeutics, Inc.
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
November 5, 2026
Rapport Therapeutics to Participate in Upcoming Investor Conferences
November 3, 2026
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
November 2, 2026
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
October 28, 2026
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
October 27, 2026
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
October 20, 2026
Rapport Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2026
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
August 24, 2026
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
August 5, 2026
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026